Search

The article from Reactions Weekly discusses two case reports of pregnant women who developed hypotension after receiving bupivacaine as spinal anesthesia during delivery. In the first case, a woman undergoing a caesarean section experienced a drop in heart rate and unrecordable blood pressure, while in the second case, a woman with hypothyroidism complained of dizziness and had a similar drop in heart rate and unmeasurable blood pressure. The hypotension in both cases was attributed to bupivacaine. [Extracted from the article]

A 26-year-old woman with complete heart block during pregnancy showed no improvement with atropine treatment. She underwent labor with epidural catheter placement and received various medications, including bupivacaine, fentanyl, epinephrine, and atropine. Despite treatment, she continued to have heart block and eventually required a permanent pacemaker placement nine months after delivery. [Extracted from the article]

A 36-year-old woman with chronic nodular prurigo and severe pruritus was treated with various medications, including topical corticosteroids, antihistamines, azathioprine, gabapentin, prednisolone, and ursodeoxycholic acid. However, these treatments were ineffective in relieving her symptoms. She was then given naloxone, which rapidly improved her pruritus and healed her skin lesions. Naloxone treatment was continued during her pregnancy, but her condition worsened due to the development of intrahepatic cholestasis of pregnancy. Despite this, she gave birth to a healthy baby boy. [Extracted from the article]

A 28-year-old woman with type 3 Von Willebrand disease experienced various complications during and after her pregnancy. She received multiple drugs for vaginal bleeding, including tranexamic acid, eptacog-alfa, prostaglandins, oxytocin, Von-Willebrand-factor, clemastine, and corticosteroids. However, she developed anaphylactic reactions and experienced a lack of efficacy with some of these medications. She underwent several procedures, including embolization and hysterectomy, and was eventually treated with off-label emicizumab, which improved her bleeding. Overall, her condition improved with emicizumab therapy. [Extracted from the article]

A 28-year-old woman with type 3 Von Willebrand disease (VWD) experienced various complications during and after her pregnancy. She received multiple drugs, including tranexamic acid, eptacog-alfa, prostaglandins, oxytocin, Von-Willebrand-factor, clemastine, and corticosteroids, for vaginal bleeding and placental retention. However, she developed anaphylactic reactions and exhibited lack of efficacy with some of these medications. She underwent several procedures, including embolization and hysterectomy, and was eventually treated with emicizumab, which improved her bleeding symptoms. [Extracted from the article]

A 34-year-old woman with systemic lupus erythematosus (SLE) experienced a lack of efficacy while taking azathioprine, hydroxychloroquine, and prednisone during breastfeeding. Despite being on these medications, she developed a flare of SLE symptoms, including pleuritis, lymphopenia, alopecia, cutaneous lupus, and increased anti-double-stranded DNA antibody titres. She eventually stopped breastfeeding and received belimumab. [Extracted from the article]

This article from Reactions Weekly describes two case studies of pregnant women with advanced chronic kidney disease (CKD) who experienced a lack of efficacy when treated with various antihypertensive medications for hypertension during pregnancy. The first patient, a 32-year-old woman, had chronic hypertension and CKD-4. She received nifedipine and labetalol but required IV labetalol during dialysis sessions for persistent severe hypertension. She delivered early preterm due to worsening severe preeclampsia. The second patient, a 36-year-old woman, had chronic hypertension and CKD-5. She received clonidine, labetalol, nifedipine, and hydralazine but required frequent IV hydralazine and labetalol for severe intradialytic hypertension. She delivered preterm due to worsening hypertension. Both patients continued dialysis postpartum and had their antihypertensive regimens adjusted. [Extracted from the article]

A literature review describes the case of a woman in her early 30s who developed impetigo herpetiformis, a skin condition, after taking hydroxychloroquine for Sjogren's syndrome during pregnancy. The woman was admitted to the hospital at 27 weeks of gestation with a rash and itching all over her body. The rash rapidly spread and turned into a deeper purple color with small clusters of pustules. The woman's hydroxychloroquine therapy was discontinued, and she received various treatments including antibiotics and immunosuppressants. She underwent an emergency caesarean section and eventually recovered from the impetigo herpetiformis with the use of ciclosporin. [Extracted from the article]

A 28-year-old woman with IgA nephropathy (IgAN) underwent kidney transplantation and was on immunosuppressant drug therapy during pregnancy. She experienced a lack of efficacy with amlodipine for hypertension and her graft function worsened despite treatment with tacrolimus, prednisolone, azathioprine, and mycophenolate-mofetil. She underwent an emergency caesarean section and after delivery, she developed severe headache, high blood pressure, and hypertensive retinopathy. Despite treatment, her graft dysfunction advanced and she was diagnosed with post-transplant thrombotic microangiopathy (TMA) secondary to IgAN. [Extracted from the article]

This article discusses two case reports of patients who developed drug-induced hypothyroidism during treatment for hyperthyroidism. In the first case, a pregnant woman with a history of Grave's disease and hypothyroidism received thiamazole and levothyroxine-sodium during her pregnancy. Her neonate also developed hypothyroidism but responded well to treatment. In the second case, a pregnant woman with a history of Grave's disease and previous miscarriages received thiamazole during her pregnancy. Her neonate also developed hypothyroidism but responded well to treatment. These cases highlight the importance of monitoring thyroid function in pregnant women receiving treatment for hyperthyroidism. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 4-month-old infant [sex not stated] developed immune-related gastroenterocolitis following in-utero exposure to pembrolizumab for maternal cancer [dosage, route and duration of treatment to reaction onset not stated]. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventIn a three-year data analysis conducted between 1·July·2020 to 30·April·2023, et al. neonate [exact age not stated; sex not stated] was described, who developed congenital malformation in the form of polydactyly following in-utero exposure to ocrelizumab for maternal multiple sclerosis [dosage, route, duration of treatment to reaction onset and outcome not stated]. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 40-year-old woman developed acute peripartum hyponatraemia during treatment with oxytocin for labour induction during delivery and postpartum bleeding. [Extracted from the article]

An adult woman received multiple drugs during pregnancy for various medical conditions, including hyperthyroidism and neutropenia. These drugs included granulocyte-colony-stimulating-factors, betamethasone, cefepime, colestyramine, hydrocortisone, thiamazole, prednisone, propylthiouracil, and propranolol. However, she also developed agranulocytosis, a condition characterized by a low level of white blood cells, as a result of treatment with thiamazole and propylthiouracil for hyperthyroidism. The specific details regarding the duration of treatment, dosage, and routes of administration were not provided. [Extracted from the article]

A study involving 31 patients found that four patients, including a 32-year-old woman and a 31-year-old woman, developed various thyroid-related conditions while being treated with alemtuzumab for multiple sclerosis. These conditions included Grave's ophthalmopathy, hypothyroidism, Hashimoto thyroiditis, and Grave's disease hyperthyroidism. One of the patients received alemtuzumab during the first trimester of her pregnancy, but the dosages, routes, and outcomes of the treatment were not specified. [Extracted from the article]

During the second and third trimesters of pregnancy, serum levels of thyroid-stimulating hormones (TSH), free triiodothyronine (T3), and free thyroxine (T4) were <=0.02 µIU/mL. Titers of the third-generation thyroid-stimulating hormone receptor antibody (TRAb) and TSH receptor-stimulating antibody (TSAb) were 5.7-21.6 IU/L and 582%, respectively. Patient 2: The female infant's serum levels of TSH, free T3, and free T4 in cord blood were 27.63 lIU/ mL, 1.5 pg/mL, and 1.3 ng/dL, respectively. [Extracted from the article]

Case 2: The mother of the fetus who had chronic hepatitis B (CHB), had been receiving treatment with tenofovir-disoproxil-fumarate for CHB during her pregnancy. Case 7: The mother of the infant who had chronic hepatitis B (CHB), had been receiving treatment with tenofovir-disoproxil-fumarate for CHB during her pregnancy. Case 6: The mother of the infant who had chronic hepatitis B (CHB), had been receiving treatment with tenofovir-disoproxil-fumarate for CHB during her pregnancy. [Extracted from the article]

The primigravid woman, presented with a several-month history of bilateral breast lumps, associated with tenderness, decreased sensation, skin thickening and pruritus at 19 weeks of gestation. Differential diagnosis included breast carcinoma, morphea profunda, granulomatous mastitis, lupus mastitis and diffuse DDA. In addition to a diagnosis of DDA, she was additionally diagnosed with gestational gigantomastia (GG), and rheumatology had concern of lupus mastitis. [Extracted from the article]